TWST: Rounding Bottom detected on 3 Apr 2026

TWST is forming a rounding_bottom pattern at $50.21, having rebounded 115.5% from its 52-week low. The setup scores 74.75 overall with solid structure (13.75/15) and volume confirmation (12.0/12), though breakout strength is moderate at 13.0/13. The pattern shows three supporting formations: a flat_base (good, 32.0 quality), followed by three_white_soldiers (moderate, 26.7 quality). Volume is 87% of 20-day average at 971k shares. RSI at 57.7 indicates neutral momentum—neither overbought nor oversold—supporting further upside potential.

In early February 2026, Twist Bioscience reported first-quarter fiscal 2026 revenue of $103.7 million, up 17% year-over-year, and raised full-year 2026 guidance to $435–440 million. This positive earnings report led to a 14.0% increase in the stock price the day after the announcement. Revenue grew 17% year-over-year to $103.7 million, surpassing analyst estimates of $100.32 million, while gross margin improved to 52.0% from 48.3% in the prior year's period. Catalysts have been substantial: On February 10, 2026, the company launched next-generation library preparation kits powered by proprietary enzymes, and on February 17, 2026, Twist Bioscience expanded its antibody discovery capabilities through a new bispecific licensing agreement. Several analysts revised their price targets upwards in early 2026; for instance, Evercore ISI Group increased its target to $52.00, Barclays to $50.00, and Guggenheim to $50.00. The current pattern has formed in the aftermath of these catalysts driving the stock up 58.3% over three months, explaining why the rounding bottom is forming NOW at elevated levels.

A successful rounding_bottom breakout above key_resistance at $35.85 would target $53.55 conservatively—only 6.7% upside from current price. However, the win_probability of 64.2% indicates slightly better-than-coin-flip odds. Volume confirmation is critical; the pattern requires breakout volume significantly above the current 0.87x ratio to validate the move. The sharp share price move after the update suggests the market is currently rewarding execution on growth, but it also raises the risk that any stumble on margins or guidance could hit sentiment harder than before. Invalidation occurs at key_support of $23.30—a 53.6% decline from current levels.

Several risks threaten this setup. According to valuation analysis, there's an indication that Twist Bioscience's share price might be on the expensive side. The ongoing net loss of $30.51 million keeps the path to adjusted EBITDA breakeven in late fiscal 2026 front and center, meaning profitability remains unproven. Beta of 1.38 indicates elevated volatility relative to the market—20% above the S&P 500. The overall market regime is bearish (-0.4), creating headwind despite the health care sector's bullish bias. Volume is trailing average at 0.87x, and insider selling activity was noted in late February 2026, which contradicts institutional enthusiasm. High expectations mean Q2 execution and next earnings results will be make-or-break events for sentiment.